The KLOW and GLOW peptide stacks share a core of GHK-Cu, BPC-157, and TB-500, but KLOW adds KPV 10 mg for additional inflammatory support. This article compares their compositions, dosages, potential benefits for skin remodeling versus healing, and research considerations, including cycle durations…
Two popular peptide protocols circulating in 2026 are the GLOW and KLOW stacks, each designed for distinct research applications. While they share significant overlap in composition and dosage, a single added component changes their primary focus. The GLOW stack contains GHK-Cu 50 mg , BPC-157 10 mg , and TB-500 10 mg , totaling 70 mg of lyophilized powder. The KLOW stack includes all three of those peptides at identical amounts but adds 10 mg of KPV, bringing the total peptide content to 80 mg.
Both stacks are presented as lyophilized powders intended for research purposes only, not for human consumption. Polar Peptides, a Canadian manufacturer, produces both formulations and states that each batch meets 99% purity verified through HPLC and mass spectrometry. The company also notes that vials contain 104% of the labeled peptide amount, and orders over $300 qualify for free shipping. These details are often cited by researchers choosing between the two protocols.
The GLOW stack is built around a high dose of GHK-Cu, a copper peptide that occurs naturally in human plasma, saliva, and urine but declines with age. Levels can drop from around 200 ng/mL at age 20 to just 80 ng/mL by age 60. Researchers believe this decline correlates with visible signs of aging in skin and hair. GHK-Cu can activate as many as 1,584 genes while suppressing 493 genes, many of which are involved in collagen synthesis, antioxidant defense, and extracellular matrix remodeling.
Roughly 71% of the GLOW protocol by weight is GHK-Cu. The remaining 20 mg consist of BPC-157 and TB-500 equally. BPC-157 promotes vasodilation through the Src-Caveolin-1-eNOS nitric oxide pathway. TB-500 appears to speed up wound healing by encouraging endothelial cell migration. These mechanisms, taken together, make the GLOW stack particularly interesting for studies involving skin firmness and tissue repair.
The GLOW stack has become a frequent topic in modern skincare research due to its combination of recovery support and potential cosmetic benefits. However, the KLOW stack offers a different balance that shifts the emphasis toward inflammatory modulation.
The KLOW stack retains the same three peptides as GLOW, GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, but includes the tripeptide KPV also known as Lys-Pro-Val at 10 mg. KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone alpha-MSH . It is believed to suppress NF-kB activation, thereby lowering inflammatory cytokine production independently of melanocortin receptors.
One study found that KPV minimized intestinal inflammation in a murine colitis model when delivered via the PepT1 transporter in colonic epithelial cells. This anti‑inflammatory action provides an additional signaling pathway not present in the GLOW stack. Because the GHK-Cu content remains the same, but the overall formula gains an anti‑inflammatory component, KLOW is often associated more with healing and recovery than with purely cosmetic outcomes.
Researchers interested in studying both skin remodeling and inflammatory support may choose to investigate each stack separately to determine which offers more potential for a specific use case.
The BPC-157 and TB-500 content is identical across the GLOW and KLOW regimens, 10 mg of each. Two distinct mechanisms support tissue repair: BPC-157 mediates nitric oxide vasodilation and upregulates growth factors; TB-500 promotes endothelial cell migration and wound repair. Both stacks also include GHK-Cu at the same strength for skin and tissue remediation. These are the points of similarity; the differences arise from the presence or absence of KPV.
Most research attention for cosmetic outcomes is directed toward the GLOW stack because of its proportionally higher GHK-Cu content 50 mg out of 70 mg . GHK-Cu stimulates collagen synthesis in human fibroblasts and activates genes linked to extracellular matrix production. KLOW contains the same copper peptide at the same absolute dose, but the addition of KPV shifts the formula toward resiliency and repair rather than firmness alone. For studies focused on skin appearance, GLOW is the more appropriate choice.
Some experts suggest that the recovery differences between KLOW and GLOW are marginal, but the KPV content in KLOW provides extra support for a healthier inflammatory response. In either stack, BPC-157 has well-documented healing capabilities. One study reported that BPC-157 accelerated Achilles tendon recovery in rat models by improving load-to-failure strength and stimulating tenocyte proliferation. Separately, Thymosin Beta-4 TB-500 was found to increase wound re‑epithelialization by up to 61% in dermal injury models.
Safety data exists for each individual component in both stacks, but no direct studies have examined the specific combinations. The general consensus among researchers is that these peptide stacks can be safe when used appropriately, but all peptides sold by Polar Peptides are formulated exclusively for laboratory research and are not intended for human consumption.
#
KLOW contains KPV for inflammatory support. All other peptide components are identical across the protocols.
According to Polar Peptides, yes. KLOW is one of the best-selling peptide stacks at the company because it unlocks a signaling pathway that would otherwise be absent in the GLOW regimen.
It depends on the research endpoint. GLOW is more appropriate for studies related to skin remodeling, while KLOW offers better insights into healing and inflammatory support. Researchers may choose to study both to determine which has more potential for a specific use case.
There is evidence for both routes regarding the individual peptides. BPC-157 has been administered intraperitoneally and intragastrically in animal models. Thymosin Beta-4 has been studied intraperitoneally in animals and intravenously in a Phase 1 human trial. GHK-Cu can be applied topically or systemically.
If reconstituted, they should be refrigerated at 2‑8 degrees Celsius. Unreconstituted lyophilized peptides can be kept in a cool, dry place away from sunlight, moisture, and heat.
The company offers domestic Canadian manufacturing and 99% purity verified by third‑party testing. A 104% fill per vial maximizes value. Free shipping is provided on orders over $300, along with customer support.
The decision between GLOW and KLOW ultimately comes down to whether KPV is needed for a given research protocol. Both stacks share the same three-peptide core at identical doses, but KLOW adds 10 mg of KPV for anti‑inflammatory signaling. Researchers must first define their endpoint, cosmetic skin remodeling or broader healing and inflammatory support, before selecting the appropriate stack.
Peptides referenced: BPC-157, TB-500, GHK-Cu, KPV, Thymosin Beta-4, Copper Tripeptide-1.
Vendors referenced: Polar Peptides.
Related reading: MOTS-c Peptide: Metabolism, Performance, and Stress Benefits, BPC-157 and TB-500 Benefits: Resilience and Repair Explained, Combination Gene Therapy and GLP-1 Drug Repairs Heart Damage in Mice, QuickFire Challenge for Oral Peptide Delivery Announced.